CV5 PHARMACOECONOMIC EVALUATION OF SIMVASTATIN VERSUS “NO TREATMENT” IN PRIMARY AND SECONDARY PREVENTION OF CORONARY HEART DISEASE (CHD) IN POLAND
0
Citation
0
Reference
10
Related Paper
Keywords:
Secondary Prevention
Primary Prevention
Secondary Prevention
Primary Prevention
Coronary disease
Cite
Citations (5)
Objective To investigate the changes of C reactive protein (CRP) in coronary heart disease (CHD) and the effect of simvastatin on CRP. Methods The plasma CRP levels were evaluated in patients with CHD and age-matched normal control group. Patients with CHD were randomized to simvastatin group and non-simvastatin group, and the CRP levels were measured before and after treatment. Results The plasma CRP levels in patients with CHD were significantly higher than those of normal controls (9.87±2.32)mg/ml vs (4.28±1.23)mg/ml(P0.01) . In simvastatin group the plasma CRP levels were significantly decreased after treatment (7.31±2.87)mg/ml, while those of non-simvastatin group remained higher level (9.22±2.54)mg/ml. The latter was significantly higher than former (t=2.34, P0.05). Conclusion Patients with CHD have significantly higher plasma CRP. Simvastatin can decrease the CRP level in patients with CHD.
Plasma levels
Cite
Citations (0)
Objective: To evaluate the effect of Simvastatin on prevention of new occurred atrial fibrillation(AF) in coronary heart disease patients.Methods: 322 patients with coronary heart disease(CHD) were randomly divided into two groups,Simvastatin group(164 cases) was given Simvastatin 10 mg and the control group(158 cases) was given routine treatment,changes of levels of high sensitive C-reactive protein in two groups were observed before and after treatment.The incidence rates of AF were measured in following-up.Results: The level of hs-CRP decreased after treatment in two groups,Simvastatin group decreased more obvious(P0.05).54 cases of the 322 patients developed AF during follow-up,8 case(4.9%) in the Simvastatin group and 46 cases(29%) in the control group,the incidence of AF in the Simvastatin group was significantly less than the control group(P0.05).Conclusion: Simvastatin can reduce the incidence of AF obviously in coronary heart disease patients.
Cite
Citations (0)
Cite
Citations (12)
Objective To evaluate the effectiveness and safety of different dose of simvastatin in the treatment of coronary heart disease in patients with dyslipidemia.Methods Totol 86 patients with definite diagnosis of coronary heart disease were divided into two groups,43 patients in each group.The low dose group were treated with 20 mg simvastatin and high dose group with 40 mg simvastatin once each night.Analyzed the changes of lipids and the untoward reactions in two groups.Results The blood lipids were decreased significantly after 12 weeks treatment(P 0.05),and the lipid improvement in hign dose group was better than in low dose group(P 0.01).Conclusion Simvastatin could significantly improve the blood lipids and is relatively reliable in treatment of coronary heart disease.
Dyslipidemia
Cite
Citations (0)
Objective:To observe the curative effect,blood lipid and C-reactive protein(CRP) change in elderly coronary heart disease by simvastatin,for accumulating clinical experience and directing clinical work. Methods:144 patients with coronary heart disease were divided into two groups. The control group(60 cases) were treated by routine treatment,the observation group(84 cases) were treated by routine treatment and simvastatin. Results:The incidence of cardiovascular events was obviously lower in the observation group than in the control group. The change of blood lipid was obviously significant in the observation group. The expression of CRP was obviously decreased in the post treatment in the two groups. But the decrease value of CRP was higher in the observation group than in the control group. Conclusion:The treatment of simvastatin can improve the curative effect and blood lipid,decrease the expression of CRP in elderly coronary heart disease. The treatment of simvastatin is worthy of being recommended in elderly patients with coronary heart disease.
Cite
Citations (0)
This work is aimed at studying the effect of a lactoovovegetarian antiatherogenic well-balanced diet, combined with the hypolipidemic drug simvastatin, on clinicohemodynamic and biochemical parameters of patients with coronary heart disease and pronounced hypercholesterolemia (TC > 7.8 mmol/l). 43 patients suffering from coronary heart disease, stenocardia under loading (functional classes II-IV) were observed. The patients of the first group (n=17) were had an antiatherogenic vegetarian diet, the patients of the second group (n=26) had the antiatherogenic mixed diet IOC. Besides a standard antianginal therapy all the patients received simvastatin in a daily doze of 20 mg. By the end of the treat ment positive changes in clinicogemodynamic and biochemical parameters were methobolism lipid observed in both the groups of patients. The comparison of lipid parameters revealed a significant and reliable decrease in the first group.
Coronary disease
Lipid Profile
Cite
Citations (0)
Objective: To explore the effect of simvastatin on the advanced aged patients with coronary heart disease.Method: 93 cases of advanced aged patients with coronary heart disease were randomly divided into the group with amount of reinforcement(n = 46) and the group with amount of routine(n = 47).The group with amount of reinforcement were given simvastatin with the dose of 40mg / d,and the group with amount of routine were given simvastatin with the dose of 20mg / d.And then examined the blood of two groups and observed the adverse response.Result: After 8 weeks,The level of TC,TG and LDL-C in two groups were reduced(P0.01),The level of HDL-C in the two groups were improved significantly(P0.01).The rate up to the standard of the group with amount of reinforcement was 71.74%(33 /46),which was higher than that of the group with amount of routine,with the rate up to the standard of 42.55%(20 /47)(X 2 = 8.08,P0.01).The rate of the adverse response between two groups has no difference(X 2 = 0.11,P 0.05).Conclusion: The effect of simvastatin with 40mg / d on the advanced aged patients with coronary heart disease is effective and safe.
Coronary disease
Cite
Citations (0)
Objective To investigate the variation of plasma inflammatory cytokine IL-6 and anti-inflammatory cytokine IL-10 in patients with coronary heart disease(CHD) and the effects of simvastatin on it.Methods 32 patients with CHD were divided into two groups:16 treated with simvastatin(10 mg/d) and 16 not treated with simvastatin.Plasma levels of IL-6 and IL-10 were detected by ELISA.C-reactive protein(CRP) was detected by turbidimetry.Results When compared with normal group,significantly increased levels of IL-6、IL-10 and CRP were observed in patients with CHD.The simvastatin treatment lowered plasma levels of IL-6 and CRP,and increased plasma level of IL-10.Conclusion Immune reaction in CHD is activated;anti-inflammatory effect of simvastatin has been shown,which may be one of its mechanisms in the prevention of atherosclerosis.
Plasma levels
Cite
Citations (0)
The authors carried out a coronary heart disease risk factor screening on 1240 people of two villages of Békés county, Hungary. The prevalence of coronary heart disease among the 969 people 35-70 years old was 12.0%, in the different age groups varied between 0.8 and 20.9%. This high prevalence could be explained by the high occurence of the different risk factors. The results of cholesterol levels were analysed according to that of Scandinavian Simvastatin Survival Study. From 35-70 years old screened people with coronary heart disease 77 had a cholesterol level between 5.5 and 8.0 mmol/l. In these patients with 20-40 mg daily dose of simvastatin during 5.4 years long treatment from 7 predicted coronary death 3, from 17 expected non fatal myocardial infarction 5, from 13 anticipated revascularisation procedures 5 would be preventable. The 5.4 years long treatment with 20 mg simvastatin calculated with the prices of July 1996 in Hungary would cost 292831 forints, from which 87847 has to be paid by the patient. If the decrease of hospitalization costs of the coronary heart disease patients treated with simvastatin is also taken into account, the drug treatment costs, according to the literature, could be reduced with additional 88%.
Coronary disease
Cite
Citations (0)